联邦制药补充披露2025年报中与牧原食品持续关连交易的合规说明

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no
responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.

The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

SUPPLEMENTAL ANNOUNCEMENT TO 2025 ANNUAL REPORT
Reference is made to the annual report of The United Laboratories international Holdings Limited
(the “Company”, together with its subsidiaries, the “Group”) for the year ended 31 December 2025
(the “2025 Annual Report”) published on 29 April 2026. Unless otherwise defined in this
announcement, capitalised terms used herein shall have the same meaning as those defined in the
2025 Annual Report.
The Company would like to supplement the following information in relation of the continued
connected transactions with Muyuan Foods for the year ended 31 December 2025 (the
“Transactions”).
One of the Suppliers, Henan Lianmu Veterinary Medicine Co., Ltd., is owned as to 60% and 40% by
the Company and Muyuan Foods, respectively. Muyuan Foods is therefore a connected person of the
Company at subsidiary level pursuant to Chapter 14A of the Listing Rules. Accordingly, the
transactions contemplated under the master sales agreement dated 3 June 2024 (the “Master
Agreement”) and the related annual caps constitute continuing connected transactions of the
Company under Chapter 14A of the Listing Rules.
The independent non-executive directors of the Company have reviewed the Transactions and
confirmed the Transactions have been entered into: (1) in the ordinary and usual course of the
business of the Group; (2) on normal commercial terms or better; and (3) according to the Master
Agreement governing the Transactions on the terms that were fair and reasonable and are in the
interest of the shareholders of the Company as a whole.
The Company’s auditor was engaged to report on the Transactions in accordance with Hong Kong
Standard on Assurance Engagement 3000 (Revised) “Assurance Engagements Other than Audits or
Reviews of Historical Financial Information” and with reference to Practice Note 740 (Revised)
“Auditor’s Letter on Continuing Connected Transactions under the Hong Kong Listing Rules” issued
by the HKICPA. The auditor has issued an unqualified letter confirming that nothing has come to its
attention that caused it to believe that the Transactions: (1) have not been approved by the Board; (2)
for the transactions involving the provision of goods and services by the Group, were not, in all
material respects, in accordance with the pricing policies of the Group; (3) were not entered into, in
all material respects, in accordance with the Master Agreement governing the Transactions; and (4)
have exceeded the annual cap as set out by the Company.
The Company confirms that it has complied with the disclosure requirements in accordance with
Chapter 14A of the Listing Rules.
-1-

The above supplemental information does not affect other information contained in the 2025 Annual
Report. All other information in the 2025 Annual Report remains correct and unchanged.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman
Hong Kong, 27 August 2026
As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon,
Ms. Choy Siu Chit, and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof.
Song Ming and Dr. Fu Qiushi as independent non-executive directors.

-2-

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確
性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或
因倚賴該等內容而引致的任何損失承擔任何責任。

The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司
(於開曼群島註冊成立的有限公司)
(股份代號 : 3933)

2025年度報告的補充公告
，連同其附屬公司統稱 「本集團」
）於二零二
茲提述聯邦制藥國際控股有限公司（「本公司」
六年四月二十九日刊發的截至二零二五年十二月三十一日止年度的年度報告（「2025年度報
告」）。除文義另有界定外，本公告所用詞彙與2025年度報告所賦予者具有相同涵義。
本公司謹此就有關截止二零二五年十二月三十一日止年度與牧原食品的持續關連交易（
「該等
交易」）提供以下額外資料。
河南聯牧獸藥有限公司（產品供應方之一）由本公司及牧原食品分別擁有60%及40%的股份。
因此，根據上市規則第14A章，牧原食品是本公司在附屬公司層面的關連人士。根據上市規則
第14A章，於日期為二零二四年六月三日的總銷售協議（「總協議」）擬進行的交易及相關年度
上限構成本公司的持續關連交易。
本公司獨立非執行董事已審閱該等交易且確認該等交易乃：(1)於本集團一般及日常業務範圍
內進行；(2)按照一般商務條款或更佳條款進行；(3)根據該等交易的總協議進行，條款公平合
理，並且符合本公司股東的整體利益。
本公司核數師已獲聘用根據香港鑒證業務準則第 3000 號（經修訂）
「非審核或審閱過往財務
資料之鑒證工作」及參考香港會計師公會發出的實務說明第 740 條（經修訂）
「關於香港上市
規則所述持續關連交易的核數師函件」就該等交易作出報告。核數師已出具一份無保留函件，
確認其並無察覺任何事項致使其認為該等交易：(1)未獲董事會批准；(2)如交易涉及由本集團
提供貨品或服務，在任何重大方面未有按本集團的定價政策定價；(3)在任何重大方面未有按
該等交易的總協議訂立；(4) 超過本公司所設的年度上限。
本公司確認已遵守上市規則第14A章的披露規定。

-1-

上述補充資料並不影響2025年度報告中載有的其他資料。2025年度報告中的所有其他資料仍
然正確及維持不變。

承董事會命
聯邦制藥國際控股有限公司
主席
蔡海山
香港，二零二六年八月二十七日
於本公告日期，董事會成員包括執行董事：蔡海山先生、梁永康先生、蔡紹哲女士及鄒鮮紅
女士；以及獨立非執行董事：張品文先生、宋敏教授及傅秋實博士。

-2-